glycoprotein	fexofenadine	25	23	false	none	The administration of the 60 mg capsule contents mixed with applesauce did not have a significant effect on the pharmacokinetics of fexofenadine in adults.  Coadministration of 180 mg fexofenadine hydrochloride tablet with a high fat meal decreased the mean area under the curve (AUC) and (Cmax) of fexofenadine by 21% and 20% respectively.  Distribution    Fexofenadine hydrochloride is 60% to 70% bound to plasma proteins, primarily albumin and α1-acid glycoprotein.  		none	87636	none	87636
glycoprotein	fexofenadine	25	23	false	none	The administration of the 60 mg capsule contents mixed with applesauce did not have a significant effect on the pharmacokinetics of fexofenadine in adults.  Coadministration of 180 mg fexofenadine hydrochloride tablet with a high fat meal decreased the mean area under the curve (AUC) and (Cmax) of fexofenadine by 21% and 20% respectively.  Distribution    Fexofenadine hydrochloride is 60% to 70% bound to plasma proteins, primarily albumin and α1-acid glycoprotein.  		none	87636	none	87636
glycoprotein	fexofenadine	25	25	true	positive	Distribution    Fexofenadine hydrochloride is 60% to 70% bound to plasma proteins, primarily albumin and α1-acid glycoprotein.  		none	87636	none	87636
glycoprotein	fexofenadine	25	25	true	positive	Distribution    Fexofenadine hydrochloride is 60% to 70% bound to plasma proteins, primarily albumin and α1-acid glycoprotein.  		none	87636	none	87636
glycoprotein	fexofenadine	25	24	true	positive	Coadministration of 180 mg fexofenadine hydrochloride tablet with a high fat meal decreased the mean area under the curve (AUC) and (Cmax) of fexofenadine by 21% and 20% respectively.  Distribution    Fexofenadine hydrochloride is 60% to 70% bound to plasma proteins, primarily albumin and α1-acid glycoprotein.  		none	87636	none	87636
glycoprotein	fexofenadine	25	24	true	positive	Coadministration of 180 mg fexofenadine hydrochloride tablet with a high fat meal decreased the mean area under the curve (AUC) and (Cmax) of fexofenadine by 21% and 20% respectively.  Distribution    Fexofenadine hydrochloride is 60% to 70% bound to plasma proteins, primarily albumin and α1-acid glycoprotein.  		none	87636	none	87636
glycoprotein	fexofenadine	25	27	true	positive	Distribution    Fexofenadine hydrochloride is 60% to 70% bound to plasma proteins, primarily albumin and α1-acid glycoprotein.  Metabolism    Approximately 5% of the total dose of fexofenadine hydrochloride was eliminated by hepatic metabolism.  Elimination    The mean elimination half-life of fexofenadine was 14.4 hours following administration of 60 mg twice daily in healthy adult subjects.  		none	87636	none	87636
glycoprotein	fexofenadine	25	27	true	positive	Distribution    Fexofenadine hydrochloride is 60% to 70% bound to plasma proteins, primarily albumin and α1-acid glycoprotein.  Metabolism    Approximately 5% of the total dose of fexofenadine hydrochloride was eliminated by hepatic metabolism.  Elimination    The mean elimination half-life of fexofenadine was 14.4 hours following administration of 60 mg twice daily in healthy adult subjects.  		none	87636	none	87636
glycoprotein	fexofenadine	25	26	true	positive	Distribution    Fexofenadine hydrochloride is 60% to 70% bound to plasma proteins, primarily albumin and α1-acid glycoprotein.  Metabolism    Approximately 5% of the total dose of fexofenadine hydrochloride was eliminated by hepatic metabolism.  		none	87636	none	87636
glycoprotein	fexofenadine	25	26	true	positive	Distribution    Fexofenadine hydrochloride is 60% to 70% bound to plasma proteins, primarily albumin and α1-acid glycoprotein.  Metabolism    Approximately 5% of the total dose of fexofenadine hydrochloride was eliminated by hepatic metabolism.  		none	87636	none	87636
glycoprotein	fexofenadine hydrochloride	25	25	true	positive	Distribution    Fexofenadine hydrochloride is 60% to 70% bound to plasma proteins, primarily albumin and α1-acid glycoprotein.  		none	87636	none	236474
glycoprotein	fexofenadine hydrochloride	25	25	true	positive	Distribution    Fexofenadine hydrochloride is 60% to 70% bound to plasma proteins, primarily albumin and α1-acid glycoprotein.  		none	87636	none	236474
glycoprotein	fexofenadine hydrochloride	25	24	true	positive	Coadministration of 180 mg fexofenadine hydrochloride tablet with a high fat meal decreased the mean area under the curve (AUC) and (Cmax) of fexofenadine by 21% and 20% respectively.  Distribution    Fexofenadine hydrochloride is 60% to 70% bound to plasma proteins, primarily albumin and α1-acid glycoprotein.  		none	87636	none	236474
glycoprotein	fexofenadine hydrochloride	25	24	true	positive	Coadministration of 180 mg fexofenadine hydrochloride tablet with a high fat meal decreased the mean area under the curve (AUC) and (Cmax) of fexofenadine by 21% and 20% respectively.  Distribution    Fexofenadine hydrochloride is 60% to 70% bound to plasma proteins, primarily albumin and α1-acid glycoprotein.  		none	87636	none	236474
glycoprotein	fexofenadine hydrochloride	25	26	true	positive	Distribution    Fexofenadine hydrochloride is 60% to 70% bound to plasma proteins, primarily albumin and α1-acid glycoprotein.  Metabolism    Approximately 5% of the total dose of fexofenadine hydrochloride was eliminated by hepatic metabolism.  		none	87636	none	236474
glycoprotein	fexofenadine hydrochloride	25	26	true	positive	Distribution    Fexofenadine hydrochloride is 60% to 70% bound to plasma proteins, primarily albumin and α1-acid glycoprotein.  Metabolism    Approximately 5% of the total dose of fexofenadine hydrochloride was eliminated by hepatic metabolism.  		none	87636	none	236474
glycoprotein	Fexofenadine hydrochloride	25	25	true	positive	Distribution    Fexofenadine hydrochloride is 60% to 70% bound to plasma proteins, primarily albumin and α1-acid glycoprotein.  		none	87636	none	236474
glycoprotein	Fexofenadine hydrochloride	25	25	true	positive	Distribution    Fexofenadine hydrochloride is 60% to 70% bound to plasma proteins, primarily albumin and α1-acid glycoprotein.  		none	87636	none	236474
glycoprotein	Fexofenadine hydrochloride	25	24	true	positive	Coadministration of 180 mg fexofenadine hydrochloride tablet with a high fat meal decreased the mean area under the curve (AUC) and (Cmax) of fexofenadine by 21% and 20% respectively.  Distribution    Fexofenadine hydrochloride is 60% to 70% bound to plasma proteins, primarily albumin and α1-acid glycoprotein.  		none	87636	none	236474
glycoprotein	Fexofenadine hydrochloride	25	24	true	positive	Coadministration of 180 mg fexofenadine hydrochloride tablet with a high fat meal decreased the mean area under the curve (AUC) and (Cmax) of fexofenadine by 21% and 20% respectively.  Distribution    Fexofenadine hydrochloride is 60% to 70% bound to plasma proteins, primarily albumin and α1-acid glycoprotein.  		none	87636	none	236474
glycoprotein	Fexofenadine hydrochloride	25	26	true	positive	Distribution    Fexofenadine hydrochloride is 60% to 70% bound to plasma proteins, primarily albumin and α1-acid glycoprotein.  Metabolism    Approximately 5% of the total dose of fexofenadine hydrochloride was eliminated by hepatic metabolism.  		none	87636	none	236474
glycoprotein	Fexofenadine hydrochloride	25	26	true	positive	Distribution    Fexofenadine hydrochloride is 60% to 70% bound to plasma proteins, primarily albumin and α1-acid glycoprotein.  Metabolism    Approximately 5% of the total dose of fexofenadine hydrochloride was eliminated by hepatic metabolism.  		none	87636	none	236474
fexofenadine	terfenadine	1	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  		87636	42330	87636	42330
fexofenadine	terfenadine	1	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  		87636	42330	87636	42330
fexofenadine	terfenadine	2	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  		87636	42330	87636	42330
fexofenadine	terfenadine	2	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  		87636	42330	87636	42330
fexofenadine	terfenadine	3	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  Fexofenadine hydrochloride inhibited antigen-induced bronchospasm in sensitized guinea pigs and histamine release from peritoneal mast cells in rats.  		87636	42330	87636	42330
fexofenadine	terfenadine	3	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  Fexofenadine hydrochloride inhibited antigen-induced bronchospasm in sensitized guinea pigs and histamine release from peritoneal mast cells in rats.  		87636	42330	87636	42330
fexofenadine	Histamine	1	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  		87636	5333	87636	D006632
fexofenadine	Histamine	1	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  		87636	5333	87636	D006632
fexofenadine	Histamine	1	3	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  Fexofenadine hydrochloride inhibited antigen-induced bronchospasm in sensitized guinea pigs and histamine release from peritoneal mast cells in rats.  		87636	5333	87636	D006632
fexofenadine	Histamine	1	3	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  Fexofenadine hydrochloride inhibited antigen-induced bronchospasm in sensitized guinea pigs and histamine release from peritoneal mast cells in rats.  		87636	5333	87636	D006632
fexofenadine	Histamine	2	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  		87636	5333	87636	D006632
fexofenadine	Histamine	2	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  		87636	5333	87636	D006632
fexofenadine	Histamine	2	3	false	none	Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  Fexofenadine hydrochloride inhibited antigen-induced bronchospasm in sensitized guinea pigs and histamine release from peritoneal mast cells in rats.  		87636	5333	87636	D006632
fexofenadine	Histamine	2	3	false	none	Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  Fexofenadine hydrochloride inhibited antigen-induced bronchospasm in sensitized guinea pigs and histamine release from peritoneal mast cells in rats.  		87636	5333	87636	D006632
fexofenadine	Histamine	3	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  Fexofenadine hydrochloride inhibited antigen-induced bronchospasm in sensitized guinea pigs and histamine release from peritoneal mast cells in rats.  		87636	5333	87636	D006632
fexofenadine	Histamine	3	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  Fexofenadine hydrochloride inhibited antigen-induced bronchospasm in sensitized guinea pigs and histamine release from peritoneal mast cells in rats.  		87636	5333	87636	D006632
fexofenadine	Histamine	3	3	false	none	Fexofenadine hydrochloride inhibited antigen-induced bronchospasm in sensitized guinea pigs and histamine release from peritoneal mast cells in rats.  		87636	5333	87636	D006632
fexofenadine	Histamine	3	3	false	none	Fexofenadine hydrochloride inhibited antigen-induced bronchospasm in sensitized guinea pigs and histamine release from peritoneal mast cells in rats.  		87636	5333	87636	D006632
fexofenadine	Histamine	7	8	false	none	Radiolabeled tissue distribution studies in rats indicated that fexofenadine does not cross the blood-brain barrier.  12.2 Pharmacodynamics    Wheal and Flare    Human histamine skin wheal and flare studies in adults following single and twice daily doses of 20 mg and 40 mg fexofenadine hydrochloride demonstrated that the drug exhibits an antihistamine effect by one hour, achieves maximum effect at 2 to 3 hours, and an effect is still seen at 12 hours.  		87636	5333	87636	D006632
fexofenadine	Histamine	7	8	false	none	Radiolabeled tissue distribution studies in rats indicated that fexofenadine does not cross the blood-brain barrier.  12.2 Pharmacodynamics    Wheal and Flare    Human histamine skin wheal and flare studies in adults following single and twice daily doses of 20 mg and 40 mg fexofenadine hydrochloride demonstrated that the drug exhibits an antihistamine effect by one hour, achieves maximum effect at 2 to 3 hours, and an effect is still seen at 12 hours.  		87636	5333	87636	D006632
fexofenadine	Histamine	8	8	true	positive	12.2 Pharmacodynamics    Wheal and Flare    Human histamine skin wheal and flare studies in adults following single and twice daily doses of 20 mg and 40 mg fexofenadine hydrochloride demonstrated that the drug exhibits an antihistamine effect by one hour, achieves maximum effect at 2 to 3 hours, and an effect is still seen at 12 hours.  		87636	5333	87636	D006632
fexofenadine	Histamine	8	8	true	positive	12.2 Pharmacodynamics    Wheal and Flare    Human histamine skin wheal and flare studies in adults following single and twice daily doses of 20 mg and 40 mg fexofenadine hydrochloride demonstrated that the drug exhibits an antihistamine effect by one hour, achieves maximum effect at 2 to 3 hours, and an effect is still seen at 12 hours.  		87636	5333	87636	D006632
fexofenadine	Histamine	13	11	true	positive	Histamine skin wheal and flare studies in 7 to 12 year old subjects showed that following a single dose of 30 mg or 60 mg, antihistamine effect was observed at one hour and reached a maximum by 3 hours.  Greater than 49% inhibition of wheal area, and 74% inhibition of flare area were maintained for 8 hours following the 30 mg and 60 mg dose.  No statistically significant increase in mean QTc interval compared to placebo was observed in 714 adult subjects with seasonal allergic rhinitis given fexofenadine hydrochloride capsules in doses of 60 mg to 240 mg twice daily for 2 weeks.  		87636	5333	87636	D006632
fexofenadine	Histamine	13	11	true	positive	Histamine skin wheal and flare studies in 7 to 12 year old subjects showed that following a single dose of 30 mg or 60 mg, antihistamine effect was observed at one hour and reached a maximum by 3 hours.  Greater than 49% inhibition of wheal area, and 74% inhibition of flare area were maintained for 8 hours following the 30 mg and 60 mg dose.  No statistically significant increase in mean QTc interval compared to placebo was observed in 714 adult subjects with seasonal allergic rhinitis given fexofenadine hydrochloride capsules in doses of 60 mg to 240 mg twice daily for 2 weeks.  		87636	5333	87636	D006632
fexofenadine	creatinine	29	31	true	positive	Because the absolute bioavailability of fexofenadine hydrochloride has not been established, it is unknown if the fecal component represents primarily unabsorbed drug or is the result of biliary excretion.  Special Populations    Pharmacokinetics in renally and hepatically impaired subjects and geriatric subjects, obtained after a single dose of 80 mg fexofenadine hydrochloride, were compared to those from healthy subjects in a separate study of similar design.  Renally Impaired    In subjects with mild to moderate (creatinine clearance 41 to 80 mL/min) and severe (creatinine clearance 11 to 40 mL/min) renal impairment, peak plasma concentrations of fexofenadine were 87% and 111% greater, respectively, and mean elimination half-lives were 59% and 72% longer, respectively, than observed in healthy subjects.  		87636	none	87636	none
fexofenadine	creatinine	29	31	true	positive	Because the absolute bioavailability of fexofenadine hydrochloride has not been established, it is unknown if the fecal component represents primarily unabsorbed drug or is the result of biliary excretion.  Special Populations    Pharmacokinetics in renally and hepatically impaired subjects and geriatric subjects, obtained after a single dose of 80 mg fexofenadine hydrochloride, were compared to those from healthy subjects in a separate study of similar design.  Renally Impaired    In subjects with mild to moderate (creatinine clearance 41 to 80 mL/min) and severe (creatinine clearance 11 to 40 mL/min) renal impairment, peak plasma concentrations of fexofenadine were 87% and 111% greater, respectively, and mean elimination half-lives were 59% and 72% longer, respectively, than observed in healthy subjects.  		87636	none	87636	none
fexofenadine	creatinine	31	32	true	positive	Renally Impaired    In subjects with mild to moderate (creatinine clearance 41 to 80 mL/min) and severe (creatinine clearance 11 to 40 mL/min) renal impairment, peak plasma concentrations of fexofenadine were 87% and 111% greater, respectively, and mean elimination half-lives were 59% and 72% longer, respectively, than observed in healthy subjects.  Peak plasma concentrations in subjects on dialysis (creatinine clearance ≤10 mL/min) were 82% greater and half-life was 31% longer than observed in healthy subjects.  		87636	none	87636	none
fexofenadine	creatinine	31	32	true	positive	Renally Impaired    In subjects with mild to moderate (creatinine clearance 41 to 80 mL/min) and severe (creatinine clearance 11 to 40 mL/min) renal impairment, peak plasma concentrations of fexofenadine were 87% and 111% greater, respectively, and mean elimination half-lives were 59% and 72% longer, respectively, than observed in healthy subjects.  Peak plasma concentrations in subjects on dialysis (creatinine clearance ≤10 mL/min) were 82% greater and half-life was 31% longer than observed in healthy subjects.  		87636	none	87636	none
fexofenadine	creatinine	31	31	true	positive	Renally Impaired    In subjects with mild to moderate (creatinine clearance 41 to 80 mL/min) and severe (creatinine clearance 11 to 40 mL/min) renal impairment, peak plasma concentrations of fexofenadine were 87% and 111% greater, respectively, and mean elimination half-lives were 59% and 72% longer, respectively, than observed in healthy subjects.  		87636	none	87636	none
fexofenadine	creatinine	31	31	true	positive	Renally Impaired    In subjects with mild to moderate (creatinine clearance 41 to 80 mL/min) and severe (creatinine clearance 11 to 40 mL/min) renal impairment, peak plasma concentrations of fexofenadine were 87% and 111% greater, respectively, and mean elimination half-lives were 59% and 72% longer, respectively, than observed in healthy subjects.  		87636	none	87636	none
fexofenadine	creatinine	30	32	true	positive	Special Populations    Pharmacokinetics in renally and hepatically impaired subjects and geriatric subjects, obtained after a single dose of 80 mg fexofenadine hydrochloride, were compared to those from healthy subjects in a separate study of similar design.  Renally Impaired    In subjects with mild to moderate (creatinine clearance 41 to 80 mL/min) and severe (creatinine clearance 11 to 40 mL/min) renal impairment, peak plasma concentrations of fexofenadine were 87% and 111% greater, respectively, and mean elimination half-lives were 59% and 72% longer, respectively, than observed in healthy subjects.  Peak plasma concentrations in subjects on dialysis (creatinine clearance ≤10 mL/min) were 82% greater and half-life was 31% longer than observed in healthy subjects.  		87636	none	87636	none
fexofenadine	creatinine	30	32	true	positive	Special Populations    Pharmacokinetics in renally and hepatically impaired subjects and geriatric subjects, obtained after a single dose of 80 mg fexofenadine hydrochloride, were compared to those from healthy subjects in a separate study of similar design.  Renally Impaired    In subjects with mild to moderate (creatinine clearance 41 to 80 mL/min) and severe (creatinine clearance 11 to 40 mL/min) renal impairment, peak plasma concentrations of fexofenadine were 87% and 111% greater, respectively, and mean elimination half-lives were 59% and 72% longer, respectively, than observed in healthy subjects.  Peak plasma concentrations in subjects on dialysis (creatinine clearance ≤10 mL/min) were 82% greater and half-life was 31% longer than observed in healthy subjects.  		87636	none	87636	none
fexofenadine	creatinine	30	31	true	positive	Special Populations    Pharmacokinetics in renally and hepatically impaired subjects and geriatric subjects, obtained after a single dose of 80 mg fexofenadine hydrochloride, were compared to those from healthy subjects in a separate study of similar design.  Renally Impaired    In subjects with mild to moderate (creatinine clearance 41 to 80 mL/min) and severe (creatinine clearance 11 to 40 mL/min) renal impairment, peak plasma concentrations of fexofenadine were 87% and 111% greater, respectively, and mean elimination half-lives were 59% and 72% longer, respectively, than observed in healthy subjects.  		87636	none	87636	none
fexofenadine	creatinine	30	31	true	positive	Special Populations    Pharmacokinetics in renally and hepatically impaired subjects and geriatric subjects, obtained after a single dose of 80 mg fexofenadine hydrochloride, were compared to those from healthy subjects in a separate study of similar design.  Renally Impaired    In subjects with mild to moderate (creatinine clearance 41 to 80 mL/min) and severe (creatinine clearance 11 to 40 mL/min) renal impairment, peak plasma concentrations of fexofenadine were 87% and 111% greater, respectively, and mean elimination half-lives were 59% and 72% longer, respectively, than observed in healthy subjects.  		87636	none	87636	none
fexofenadine	creatinine	34	32	true	positive	Peak plasma concentrations in subjects on dialysis (creatinine clearance ≤10 mL/min) were 82% greater and half-life was 31% longer than observed in healthy subjects.  Based on increases in bioavailability and half-life, a dose of 60 mg once daily is recommended as the starting dose in adult patients with decreased renal function.  For pediatric patients with decreased renal function, the recommended starting dose of fexofenadine is 30 mg once daily for patients 2 to 11 years of age and 15 mg once daily for patients 6 months to less than 2 years of age.  		87636	none	87636	none
fexofenadine	creatinine	34	32	true	positive	Peak plasma concentrations in subjects on dialysis (creatinine clearance ≤10 mL/min) were 82% greater and half-life was 31% longer than observed in healthy subjects.  Based on increases in bioavailability and half-life, a dose of 60 mg once daily is recommended as the starting dose in adult patients with decreased renal function.  For pediatric patients with decreased renal function, the recommended starting dose of fexofenadine is 30 mg once daily for patients 2 to 11 years of age and 15 mg once daily for patients 6 months to less than 2 years of age.  		87636	none	87636	none
fexofenadine	histamine	1	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  		87636	5333	87636	D006632
fexofenadine	histamine	1	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  		87636	5333	87636	D006632
fexofenadine	histamine	1	3	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  Fexofenadine hydrochloride inhibited antigen-induced bronchospasm in sensitized guinea pigs and histamine release from peritoneal mast cells in rats.  		87636	5333	87636	D006632
fexofenadine	histamine	1	3	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  Fexofenadine hydrochloride inhibited antigen-induced bronchospasm in sensitized guinea pigs and histamine release from peritoneal mast cells in rats.  		87636	5333	87636	D006632
fexofenadine	histamine	2	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  		87636	5333	87636	D006632
fexofenadine	histamine	2	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  		87636	5333	87636	D006632
fexofenadine	histamine	2	3	false	none	Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  Fexofenadine hydrochloride inhibited antigen-induced bronchospasm in sensitized guinea pigs and histamine release from peritoneal mast cells in rats.  		87636	5333	87636	D006632
fexofenadine	histamine	2	3	false	none	Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  Fexofenadine hydrochloride inhibited antigen-induced bronchospasm in sensitized guinea pigs and histamine release from peritoneal mast cells in rats.  		87636	5333	87636	D006632
fexofenadine	histamine	3	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  Fexofenadine hydrochloride inhibited antigen-induced bronchospasm in sensitized guinea pigs and histamine release from peritoneal mast cells in rats.  		87636	5333	87636	D006632
fexofenadine	histamine	3	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  Fexofenadine hydrochloride inhibited antigen-induced bronchospasm in sensitized guinea pigs and histamine release from peritoneal mast cells in rats.  		87636	5333	87636	D006632
fexofenadine	histamine	3	3	false	none	Fexofenadine hydrochloride inhibited antigen-induced bronchospasm in sensitized guinea pigs and histamine release from peritoneal mast cells in rats.  		87636	5333	87636	D006632
fexofenadine	histamine	3	3	false	none	Fexofenadine hydrochloride inhibited antigen-induced bronchospasm in sensitized guinea pigs and histamine release from peritoneal mast cells in rats.  		87636	5333	87636	D006632
fexofenadine	histamine	7	8	false	none	Radiolabeled tissue distribution studies in rats indicated that fexofenadine does not cross the blood-brain barrier.  12.2 Pharmacodynamics    Wheal and Flare    Human histamine skin wheal and flare studies in adults following single and twice daily doses of 20 mg and 40 mg fexofenadine hydrochloride demonstrated that the drug exhibits an antihistamine effect by one hour, achieves maximum effect at 2 to 3 hours, and an effect is still seen at 12 hours.  		87636	5333	87636	D006632
fexofenadine	histamine	7	8	false	none	Radiolabeled tissue distribution studies in rats indicated that fexofenadine does not cross the blood-brain barrier.  12.2 Pharmacodynamics    Wheal and Flare    Human histamine skin wheal and flare studies in adults following single and twice daily doses of 20 mg and 40 mg fexofenadine hydrochloride demonstrated that the drug exhibits an antihistamine effect by one hour, achieves maximum effect at 2 to 3 hours, and an effect is still seen at 12 hours.  		87636	5333	87636	D006632
fexofenadine	histamine	8	8	true	positive	12.2 Pharmacodynamics    Wheal and Flare    Human histamine skin wheal and flare studies in adults following single and twice daily doses of 20 mg and 40 mg fexofenadine hydrochloride demonstrated that the drug exhibits an antihistamine effect by one hour, achieves maximum effect at 2 to 3 hours, and an effect is still seen at 12 hours.  		87636	5333	87636	D006632
fexofenadine	histamine	8	8	true	positive	12.2 Pharmacodynamics    Wheal and Flare    Human histamine skin wheal and flare studies in adults following single and twice daily doses of 20 mg and 40 mg fexofenadine hydrochloride demonstrated that the drug exhibits an antihistamine effect by one hour, achieves maximum effect at 2 to 3 hours, and an effect is still seen at 12 hours.  		87636	5333	87636	D006632
fexofenadine	histamine	13	11	true	positive	Histamine skin wheal and flare studies in 7 to 12 year old subjects showed that following a single dose of 30 mg or 60 mg, antihistamine effect was observed at one hour and reached a maximum by 3 hours.  Greater than 49% inhibition of wheal area, and 74% inhibition of flare area were maintained for 8 hours following the 30 mg and 60 mg dose.  No statistically significant increase in mean QTc interval compared to placebo was observed in 714 adult subjects with seasonal allergic rhinitis given fexofenadine hydrochloride capsules in doses of 60 mg to 240 mg twice daily for 2 weeks.  		87636	5333	87636	D006632
fexofenadine	histamine	13	11	true	positive	Histamine skin wheal and flare studies in 7 to 12 year old subjects showed that following a single dose of 30 mg or 60 mg, antihistamine effect was observed at one hour and reached a maximum by 3 hours.  Greater than 49% inhibition of wheal area, and 74% inhibition of flare area were maintained for 8 hours following the 30 mg and 60 mg dose.  No statistically significant increase in mean QTc interval compared to placebo was observed in 714 adult subjects with seasonal allergic rhinitis given fexofenadine hydrochloride capsules in doses of 60 mg to 240 mg twice daily for 2 weeks.  		87636	5333	87636	D006632
fexofenadine hydrochloride	terfenadine	1	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  		87636	42330	236474	42330
fexofenadine hydrochloride	terfenadine	1	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  		87636	42330	236474	42330
fexofenadine hydrochloride	terfenadine	2	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  		87636	42330	236474	42330
fexofenadine hydrochloride	terfenadine	2	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  		87636	42330	236474	42330
fexofenadine hydrochloride	terfenadine	3	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  Fexofenadine hydrochloride inhibited antigen-induced bronchospasm in sensitized guinea pigs and histamine release from peritoneal mast cells in rats.  		87636	42330	236474	42330
fexofenadine hydrochloride	terfenadine	3	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  Fexofenadine hydrochloride inhibited antigen-induced bronchospasm in sensitized guinea pigs and histamine release from peritoneal mast cells in rats.  		87636	42330	236474	42330
fexofenadine hydrochloride	Histamine	1	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  		87636	5333	236474	D006632
fexofenadine hydrochloride	Histamine	1	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  		87636	5333	236474	D006632
fexofenadine hydrochloride	Histamine	1	3	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  Fexofenadine hydrochloride inhibited antigen-induced bronchospasm in sensitized guinea pigs and histamine release from peritoneal mast cells in rats.  		87636	5333	236474	D006632
fexofenadine hydrochloride	Histamine	1	3	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  Fexofenadine hydrochloride inhibited antigen-induced bronchospasm in sensitized guinea pigs and histamine release from peritoneal mast cells in rats.  		87636	5333	236474	D006632
fexofenadine hydrochloride	Histamine	2	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  		87636	5333	236474	D006632
fexofenadine hydrochloride	Histamine	2	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  		87636	5333	236474	D006632
fexofenadine hydrochloride	Histamine	2	3	false	none	Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  Fexofenadine hydrochloride inhibited antigen-induced bronchospasm in sensitized guinea pigs and histamine release from peritoneal mast cells in rats.  		87636	5333	236474	D006632
fexofenadine hydrochloride	Histamine	2	3	false	none	Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  Fexofenadine hydrochloride inhibited antigen-induced bronchospasm in sensitized guinea pigs and histamine release from peritoneal mast cells in rats.  		87636	5333	236474	D006632
fexofenadine hydrochloride	Histamine	3	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  Fexofenadine hydrochloride inhibited antigen-induced bronchospasm in sensitized guinea pigs and histamine release from peritoneal mast cells in rats.  		87636	5333	236474	D006632
fexofenadine hydrochloride	Histamine	3	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  Fexofenadine hydrochloride inhibited antigen-induced bronchospasm in sensitized guinea pigs and histamine release from peritoneal mast cells in rats.  		87636	5333	236474	D006632
fexofenadine hydrochloride	Histamine	3	3	false	none	Fexofenadine hydrochloride inhibited antigen-induced bronchospasm in sensitized guinea pigs and histamine release from peritoneal mast cells in rats.  		87636	5333	236474	D006632
fexofenadine hydrochloride	Histamine	3	3	false	none	Fexofenadine hydrochloride inhibited antigen-induced bronchospasm in sensitized guinea pigs and histamine release from peritoneal mast cells in rats.  		87636	5333	236474	D006632
fexofenadine hydrochloride	Histamine	8	8	true	positive	12.2 Pharmacodynamics    Wheal and Flare    Human histamine skin wheal and flare studies in adults following single and twice daily doses of 20 mg and 40 mg fexofenadine hydrochloride demonstrated that the drug exhibits an antihistamine effect by one hour, achieves maximum effect at 2 to 3 hours, and an effect is still seen at 12 hours.  		87636	5333	236474	D006632
fexofenadine hydrochloride	Histamine	8	8	true	positive	12.2 Pharmacodynamics    Wheal and Flare    Human histamine skin wheal and flare studies in adults following single and twice daily doses of 20 mg and 40 mg fexofenadine hydrochloride demonstrated that the drug exhibits an antihistamine effect by one hour, achieves maximum effect at 2 to 3 hours, and an effect is still seen at 12 hours.  		87636	5333	236474	D006632
fexofenadine hydrochloride	Histamine	13	11	true	positive	Histamine skin wheal and flare studies in 7 to 12 year old subjects showed that following a single dose of 30 mg or 60 mg, antihistamine effect was observed at one hour and reached a maximum by 3 hours.  Greater than 49% inhibition of wheal area, and 74% inhibition of flare area were maintained for 8 hours following the 30 mg and 60 mg dose.  No statistically significant increase in mean QTc interval compared to placebo was observed in 714 adult subjects with seasonal allergic rhinitis given fexofenadine hydrochloride capsules in doses of 60 mg to 240 mg twice daily for 2 weeks.  		87636	5333	236474	D006632
fexofenadine hydrochloride	Histamine	13	11	true	positive	Histamine skin wheal and flare studies in 7 to 12 year old subjects showed that following a single dose of 30 mg or 60 mg, antihistamine effect was observed at one hour and reached a maximum by 3 hours.  Greater than 49% inhibition of wheal area, and 74% inhibition of flare area were maintained for 8 hours following the 30 mg and 60 mg dose.  No statistically significant increase in mean QTc interval compared to placebo was observed in 714 adult subjects with seasonal allergic rhinitis given fexofenadine hydrochloride capsules in doses of 60 mg to 240 mg twice daily for 2 weeks.  		87636	5333	236474	D006632
fexofenadine hydrochloride	creatinine	29	31	true	positive	Because the absolute bioavailability of fexofenadine hydrochloride has not been established, it is unknown if the fecal component represents primarily unabsorbed drug or is the result of biliary excretion.  Special Populations    Pharmacokinetics in renally and hepatically impaired subjects and geriatric subjects, obtained after a single dose of 80 mg fexofenadine hydrochloride, were compared to those from healthy subjects in a separate study of similar design.  Renally Impaired    In subjects with mild to moderate (creatinine clearance 41 to 80 mL/min) and severe (creatinine clearance 11 to 40 mL/min) renal impairment, peak plasma concentrations of fexofenadine were 87% and 111% greater, respectively, and mean elimination half-lives were 59% and 72% longer, respectively, than observed in healthy subjects.  		87636	none	236474	none
fexofenadine hydrochloride	creatinine	29	31	true	positive	Because the absolute bioavailability of fexofenadine hydrochloride has not been established, it is unknown if the fecal component represents primarily unabsorbed drug or is the result of biliary excretion.  Special Populations    Pharmacokinetics in renally and hepatically impaired subjects and geriatric subjects, obtained after a single dose of 80 mg fexofenadine hydrochloride, were compared to those from healthy subjects in a separate study of similar design.  Renally Impaired    In subjects with mild to moderate (creatinine clearance 41 to 80 mL/min) and severe (creatinine clearance 11 to 40 mL/min) renal impairment, peak plasma concentrations of fexofenadine were 87% and 111% greater, respectively, and mean elimination half-lives were 59% and 72% longer, respectively, than observed in healthy subjects.  		87636	none	236474	none
fexofenadine hydrochloride	creatinine	30	32	true	positive	Special Populations    Pharmacokinetics in renally and hepatically impaired subjects and geriatric subjects, obtained after a single dose of 80 mg fexofenadine hydrochloride, were compared to those from healthy subjects in a separate study of similar design.  Renally Impaired    In subjects with mild to moderate (creatinine clearance 41 to 80 mL/min) and severe (creatinine clearance 11 to 40 mL/min) renal impairment, peak plasma concentrations of fexofenadine were 87% and 111% greater, respectively, and mean elimination half-lives were 59% and 72% longer, respectively, than observed in healthy subjects.  Peak plasma concentrations in subjects on dialysis (creatinine clearance ≤10 mL/min) were 82% greater and half-life was 31% longer than observed in healthy subjects.  		87636	none	236474	none
fexofenadine hydrochloride	creatinine	30	32	true	positive	Special Populations    Pharmacokinetics in renally and hepatically impaired subjects and geriatric subjects, obtained after a single dose of 80 mg fexofenadine hydrochloride, were compared to those from healthy subjects in a separate study of similar design.  Renally Impaired    In subjects with mild to moderate (creatinine clearance 41 to 80 mL/min) and severe (creatinine clearance 11 to 40 mL/min) renal impairment, peak plasma concentrations of fexofenadine were 87% and 111% greater, respectively, and mean elimination half-lives were 59% and 72% longer, respectively, than observed in healthy subjects.  Peak plasma concentrations in subjects on dialysis (creatinine clearance ≤10 mL/min) were 82% greater and half-life was 31% longer than observed in healthy subjects.  		87636	none	236474	none
fexofenadine hydrochloride	creatinine	30	31	true	positive	Special Populations    Pharmacokinetics in renally and hepatically impaired subjects and geriatric subjects, obtained after a single dose of 80 mg fexofenadine hydrochloride, were compared to those from healthy subjects in a separate study of similar design.  Renally Impaired    In subjects with mild to moderate (creatinine clearance 41 to 80 mL/min) and severe (creatinine clearance 11 to 40 mL/min) renal impairment, peak plasma concentrations of fexofenadine were 87% and 111% greater, respectively, and mean elimination half-lives were 59% and 72% longer, respectively, than observed in healthy subjects.  		87636	none	236474	none
fexofenadine hydrochloride	creatinine	30	31	true	positive	Special Populations    Pharmacokinetics in renally and hepatically impaired subjects and geriatric subjects, obtained after a single dose of 80 mg fexofenadine hydrochloride, were compared to those from healthy subjects in a separate study of similar design.  Renally Impaired    In subjects with mild to moderate (creatinine clearance 41 to 80 mL/min) and severe (creatinine clearance 11 to 40 mL/min) renal impairment, peak plasma concentrations of fexofenadine were 87% and 111% greater, respectively, and mean elimination half-lives were 59% and 72% longer, respectively, than observed in healthy subjects.  		87636	none	236474	none
fexofenadine hydrochloride	histamine	1	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  		87636	5333	236474	D006632
fexofenadine hydrochloride	histamine	1	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  		87636	5333	236474	D006632
fexofenadine hydrochloride	histamine	1	3	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  Fexofenadine hydrochloride inhibited antigen-induced bronchospasm in sensitized guinea pigs and histamine release from peritoneal mast cells in rats.  		87636	5333	236474	D006632
fexofenadine hydrochloride	histamine	1	3	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  Fexofenadine hydrochloride inhibited antigen-induced bronchospasm in sensitized guinea pigs and histamine release from peritoneal mast cells in rats.  		87636	5333	236474	D006632
fexofenadine hydrochloride	histamine	2	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  		87636	5333	236474	D006632
fexofenadine hydrochloride	histamine	2	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  		87636	5333	236474	D006632
fexofenadine hydrochloride	histamine	2	3	false	none	Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  Fexofenadine hydrochloride inhibited antigen-induced bronchospasm in sensitized guinea pigs and histamine release from peritoneal mast cells in rats.  		87636	5333	236474	D006632
fexofenadine hydrochloride	histamine	2	3	false	none	Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  Fexofenadine hydrochloride inhibited antigen-induced bronchospasm in sensitized guinea pigs and histamine release from peritoneal mast cells in rats.  		87636	5333	236474	D006632
fexofenadine hydrochloride	histamine	3	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  Fexofenadine hydrochloride inhibited antigen-induced bronchospasm in sensitized guinea pigs and histamine release from peritoneal mast cells in rats.  		87636	5333	236474	D006632
fexofenadine hydrochloride	histamine	3	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  Fexofenadine hydrochloride inhibited antigen-induced bronchospasm in sensitized guinea pigs and histamine release from peritoneal mast cells in rats.  		87636	5333	236474	D006632
fexofenadine hydrochloride	histamine	3	3	false	none	Fexofenadine hydrochloride inhibited antigen-induced bronchospasm in sensitized guinea pigs and histamine release from peritoneal mast cells in rats.  		87636	5333	236474	D006632
fexofenadine hydrochloride	histamine	3	3	false	none	Fexofenadine hydrochloride inhibited antigen-induced bronchospasm in sensitized guinea pigs and histamine release from peritoneal mast cells in rats.  		87636	5333	236474	D006632
fexofenadine hydrochloride	histamine	8	8	true	positive	12.2 Pharmacodynamics    Wheal and Flare    Human histamine skin wheal and flare studies in adults following single and twice daily doses of 20 mg and 40 mg fexofenadine hydrochloride demonstrated that the drug exhibits an antihistamine effect by one hour, achieves maximum effect at 2 to 3 hours, and an effect is still seen at 12 hours.  		87636	5333	236474	D006632
fexofenadine hydrochloride	histamine	8	8	true	positive	12.2 Pharmacodynamics    Wheal and Flare    Human histamine skin wheal and flare studies in adults following single and twice daily doses of 20 mg and 40 mg fexofenadine hydrochloride demonstrated that the drug exhibits an antihistamine effect by one hour, achieves maximum effect at 2 to 3 hours, and an effect is still seen at 12 hours.  		87636	5333	236474	D006632
fexofenadine hydrochloride	histamine	13	11	true	positive	Histamine skin wheal and flare studies in 7 to 12 year old subjects showed that following a single dose of 30 mg or 60 mg, antihistamine effect was observed at one hour and reached a maximum by 3 hours.  Greater than 49% inhibition of wheal area, and 74% inhibition of flare area were maintained for 8 hours following the 30 mg and 60 mg dose.  No statistically significant increase in mean QTc interval compared to placebo was observed in 714 adult subjects with seasonal allergic rhinitis given fexofenadine hydrochloride capsules in doses of 60 mg to 240 mg twice daily for 2 weeks.  		87636	5333	236474	D006632
fexofenadine hydrochloride	histamine	13	11	true	positive	Histamine skin wheal and flare studies in 7 to 12 year old subjects showed that following a single dose of 30 mg or 60 mg, antihistamine effect was observed at one hour and reached a maximum by 3 hours.  Greater than 49% inhibition of wheal area, and 74% inhibition of flare area were maintained for 8 hours following the 30 mg and 60 mg dose.  No statistically significant increase in mean QTc interval compared to placebo was observed in 714 adult subjects with seasonal allergic rhinitis given fexofenadine hydrochloride capsules in doses of 60 mg to 240 mg twice daily for 2 weeks.  		87636	5333	236474	D006632
Fexofenadine hydrochloride	terfenadine	1	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  		87636	42330	236474	42330
Fexofenadine hydrochloride	terfenadine	1	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  		87636	42330	236474	42330
Fexofenadine hydrochloride	terfenadine	2	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  		87636	42330	236474	42330
Fexofenadine hydrochloride	terfenadine	2	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  		87636	42330	236474	42330
Fexofenadine hydrochloride	terfenadine	3	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  Fexofenadine hydrochloride inhibited antigen-induced bronchospasm in sensitized guinea pigs and histamine release from peritoneal mast cells in rats.  		87636	42330	236474	42330
Fexofenadine hydrochloride	terfenadine	3	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  Fexofenadine hydrochloride inhibited antigen-induced bronchospasm in sensitized guinea pigs and histamine release from peritoneal mast cells in rats.  		87636	42330	236474	42330
Fexofenadine hydrochloride	Histamine	1	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  		87636	5333	236474	D006632
Fexofenadine hydrochloride	Histamine	1	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  		87636	5333	236474	D006632
Fexofenadine hydrochloride	Histamine	1	3	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  Fexofenadine hydrochloride inhibited antigen-induced bronchospasm in sensitized guinea pigs and histamine release from peritoneal mast cells in rats.  		87636	5333	236474	D006632
Fexofenadine hydrochloride	Histamine	1	3	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  Fexofenadine hydrochloride inhibited antigen-induced bronchospasm in sensitized guinea pigs and histamine release from peritoneal mast cells in rats.  		87636	5333	236474	D006632
Fexofenadine hydrochloride	Histamine	2	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  		87636	5333	236474	D006632
Fexofenadine hydrochloride	Histamine	2	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  		87636	5333	236474	D006632
Fexofenadine hydrochloride	Histamine	2	3	false	none	Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  Fexofenadine hydrochloride inhibited antigen-induced bronchospasm in sensitized guinea pigs and histamine release from peritoneal mast cells in rats.  		87636	5333	236474	D006632
Fexofenadine hydrochloride	Histamine	2	3	false	none	Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  Fexofenadine hydrochloride inhibited antigen-induced bronchospasm in sensitized guinea pigs and histamine release from peritoneal mast cells in rats.  		87636	5333	236474	D006632
Fexofenadine hydrochloride	Histamine	3	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  Fexofenadine hydrochloride inhibited antigen-induced bronchospasm in sensitized guinea pigs and histamine release from peritoneal mast cells in rats.  		87636	5333	236474	D006632
Fexofenadine hydrochloride	Histamine	3	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  Fexofenadine hydrochloride inhibited antigen-induced bronchospasm in sensitized guinea pigs and histamine release from peritoneal mast cells in rats.  		87636	5333	236474	D006632
Fexofenadine hydrochloride	Histamine	3	3	false	none	Fexofenadine hydrochloride inhibited antigen-induced bronchospasm in sensitized guinea pigs and histamine release from peritoneal mast cells in rats.  		87636	5333	236474	D006632
Fexofenadine hydrochloride	Histamine	3	3	false	none	Fexofenadine hydrochloride inhibited antigen-induced bronchospasm in sensitized guinea pigs and histamine release from peritoneal mast cells in rats.  		87636	5333	236474	D006632
Fexofenadine hydrochloride	Histamine	8	8	true	positive	12.2 Pharmacodynamics    Wheal and Flare    Human histamine skin wheal and flare studies in adults following single and twice daily doses of 20 mg and 40 mg fexofenadine hydrochloride demonstrated that the drug exhibits an antihistamine effect by one hour, achieves maximum effect at 2 to 3 hours, and an effect is still seen at 12 hours.  		87636	5333	236474	D006632
Fexofenadine hydrochloride	Histamine	8	8	true	positive	12.2 Pharmacodynamics    Wheal and Flare    Human histamine skin wheal and flare studies in adults following single and twice daily doses of 20 mg and 40 mg fexofenadine hydrochloride demonstrated that the drug exhibits an antihistamine effect by one hour, achieves maximum effect at 2 to 3 hours, and an effect is still seen at 12 hours.  		87636	5333	236474	D006632
Fexofenadine hydrochloride	Histamine	13	11	true	positive	Histamine skin wheal and flare studies in 7 to 12 year old subjects showed that following a single dose of 30 mg or 60 mg, antihistamine effect was observed at one hour and reached a maximum by 3 hours.  Greater than 49% inhibition of wheal area, and 74% inhibition of flare area were maintained for 8 hours following the 30 mg and 60 mg dose.  No statistically significant increase in mean QTc interval compared to placebo was observed in 714 adult subjects with seasonal allergic rhinitis given fexofenadine hydrochloride capsules in doses of 60 mg to 240 mg twice daily for 2 weeks.  		87636	5333	236474	D006632
Fexofenadine hydrochloride	Histamine	13	11	true	positive	Histamine skin wheal and flare studies in 7 to 12 year old subjects showed that following a single dose of 30 mg or 60 mg, antihistamine effect was observed at one hour and reached a maximum by 3 hours.  Greater than 49% inhibition of wheal area, and 74% inhibition of flare area were maintained for 8 hours following the 30 mg and 60 mg dose.  No statistically significant increase in mean QTc interval compared to placebo was observed in 714 adult subjects with seasonal allergic rhinitis given fexofenadine hydrochloride capsules in doses of 60 mg to 240 mg twice daily for 2 weeks.  		87636	5333	236474	D006632
Fexofenadine hydrochloride	creatinine	29	31	true	positive	Because the absolute bioavailability of fexofenadine hydrochloride has not been established, it is unknown if the fecal component represents primarily unabsorbed drug or is the result of biliary excretion.  Special Populations    Pharmacokinetics in renally and hepatically impaired subjects and geriatric subjects, obtained after a single dose of 80 mg fexofenadine hydrochloride, were compared to those from healthy subjects in a separate study of similar design.  Renally Impaired    In subjects with mild to moderate (creatinine clearance 41 to 80 mL/min) and severe (creatinine clearance 11 to 40 mL/min) renal impairment, peak plasma concentrations of fexofenadine were 87% and 111% greater, respectively, and mean elimination half-lives were 59% and 72% longer, respectively, than observed in healthy subjects.  		87636	none	236474	none
Fexofenadine hydrochloride	creatinine	29	31	true	positive	Because the absolute bioavailability of fexofenadine hydrochloride has not been established, it is unknown if the fecal component represents primarily unabsorbed drug or is the result of biliary excretion.  Special Populations    Pharmacokinetics in renally and hepatically impaired subjects and geriatric subjects, obtained after a single dose of 80 mg fexofenadine hydrochloride, were compared to those from healthy subjects in a separate study of similar design.  Renally Impaired    In subjects with mild to moderate (creatinine clearance 41 to 80 mL/min) and severe (creatinine clearance 11 to 40 mL/min) renal impairment, peak plasma concentrations of fexofenadine were 87% and 111% greater, respectively, and mean elimination half-lives were 59% and 72% longer, respectively, than observed in healthy subjects.  		87636	none	236474	none
Fexofenadine hydrochloride	creatinine	30	32	true	positive	Special Populations    Pharmacokinetics in renally and hepatically impaired subjects and geriatric subjects, obtained after a single dose of 80 mg fexofenadine hydrochloride, were compared to those from healthy subjects in a separate study of similar design.  Renally Impaired    In subjects with mild to moderate (creatinine clearance 41 to 80 mL/min) and severe (creatinine clearance 11 to 40 mL/min) renal impairment, peak plasma concentrations of fexofenadine were 87% and 111% greater, respectively, and mean elimination half-lives were 59% and 72% longer, respectively, than observed in healthy subjects.  Peak plasma concentrations in subjects on dialysis (creatinine clearance ≤10 mL/min) were 82% greater and half-life was 31% longer than observed in healthy subjects.  		87636	none	236474	none
Fexofenadine hydrochloride	creatinine	30	32	true	positive	Special Populations    Pharmacokinetics in renally and hepatically impaired subjects and geriatric subjects, obtained after a single dose of 80 mg fexofenadine hydrochloride, were compared to those from healthy subjects in a separate study of similar design.  Renally Impaired    In subjects with mild to moderate (creatinine clearance 41 to 80 mL/min) and severe (creatinine clearance 11 to 40 mL/min) renal impairment, peak plasma concentrations of fexofenadine were 87% and 111% greater, respectively, and mean elimination half-lives were 59% and 72% longer, respectively, than observed in healthy subjects.  Peak plasma concentrations in subjects on dialysis (creatinine clearance ≤10 mL/min) were 82% greater and half-life was 31% longer than observed in healthy subjects.  		87636	none	236474	none
Fexofenadine hydrochloride	creatinine	30	31	true	positive	Special Populations    Pharmacokinetics in renally and hepatically impaired subjects and geriatric subjects, obtained after a single dose of 80 mg fexofenadine hydrochloride, were compared to those from healthy subjects in a separate study of similar design.  Renally Impaired    In subjects with mild to moderate (creatinine clearance 41 to 80 mL/min) and severe (creatinine clearance 11 to 40 mL/min) renal impairment, peak plasma concentrations of fexofenadine were 87% and 111% greater, respectively, and mean elimination half-lives were 59% and 72% longer, respectively, than observed in healthy subjects.  		87636	none	236474	none
Fexofenadine hydrochloride	creatinine	30	31	true	positive	Special Populations    Pharmacokinetics in renally and hepatically impaired subjects and geriatric subjects, obtained after a single dose of 80 mg fexofenadine hydrochloride, were compared to those from healthy subjects in a separate study of similar design.  Renally Impaired    In subjects with mild to moderate (creatinine clearance 41 to 80 mL/min) and severe (creatinine clearance 11 to 40 mL/min) renal impairment, peak plasma concentrations of fexofenadine were 87% and 111% greater, respectively, and mean elimination half-lives were 59% and 72% longer, respectively, than observed in healthy subjects.  		87636	none	236474	none
Fexofenadine hydrochloride	histamine	1	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  		87636	5333	236474	D006632
Fexofenadine hydrochloride	histamine	1	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  		87636	5333	236474	D006632
Fexofenadine hydrochloride	histamine	1	3	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  Fexofenadine hydrochloride inhibited antigen-induced bronchospasm in sensitized guinea pigs and histamine release from peritoneal mast cells in rats.  		87636	5333	236474	D006632
Fexofenadine hydrochloride	histamine	1	3	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  Fexofenadine hydrochloride inhibited antigen-induced bronchospasm in sensitized guinea pigs and histamine release from peritoneal mast cells in rats.  		87636	5333	236474	D006632
Fexofenadine hydrochloride	histamine	2	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  		87636	5333	236474	D006632
Fexofenadine hydrochloride	histamine	2	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  		87636	5333	236474	D006632
Fexofenadine hydrochloride	histamine	2	3	false	none	Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  Fexofenadine hydrochloride inhibited antigen-induced bronchospasm in sensitized guinea pigs and histamine release from peritoneal mast cells in rats.  		87636	5333	236474	D006632
Fexofenadine hydrochloride	histamine	2	3	false	none	Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  Fexofenadine hydrochloride inhibited antigen-induced bronchospasm in sensitized guinea pigs and histamine release from peritoneal mast cells in rats.  		87636	5333	236474	D006632
Fexofenadine hydrochloride	histamine	3	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  Fexofenadine hydrochloride inhibited antigen-induced bronchospasm in sensitized guinea pigs and histamine release from peritoneal mast cells in rats.  		87636	5333	236474	D006632
Fexofenadine hydrochloride	histamine	3	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  Fexofenadine hydrochloride inhibited antigen-induced bronchospasm in sensitized guinea pigs and histamine release from peritoneal mast cells in rats.  		87636	5333	236474	D006632
Fexofenadine hydrochloride	histamine	3	3	false	none	Fexofenadine hydrochloride inhibited antigen-induced bronchospasm in sensitized guinea pigs and histamine release from peritoneal mast cells in rats.  		87636	5333	236474	D006632
Fexofenadine hydrochloride	histamine	3	3	false	none	Fexofenadine hydrochloride inhibited antigen-induced bronchospasm in sensitized guinea pigs and histamine release from peritoneal mast cells in rats.  		87636	5333	236474	D006632
Fexofenadine hydrochloride	histamine	8	8	true	positive	12.2 Pharmacodynamics    Wheal and Flare    Human histamine skin wheal and flare studies in adults following single and twice daily doses of 20 mg and 40 mg fexofenadine hydrochloride demonstrated that the drug exhibits an antihistamine effect by one hour, achieves maximum effect at 2 to 3 hours, and an effect is still seen at 12 hours.  		87636	5333	236474	D006632
Fexofenadine hydrochloride	histamine	8	8	true	positive	12.2 Pharmacodynamics    Wheal and Flare    Human histamine skin wheal and flare studies in adults following single and twice daily doses of 20 mg and 40 mg fexofenadine hydrochloride demonstrated that the drug exhibits an antihistamine effect by one hour, achieves maximum effect at 2 to 3 hours, and an effect is still seen at 12 hours.  		87636	5333	236474	D006632
Fexofenadine hydrochloride	histamine	13	11	true	positive	Histamine skin wheal and flare studies in 7 to 12 year old subjects showed that following a single dose of 30 mg or 60 mg, antihistamine effect was observed at one hour and reached a maximum by 3 hours.  Greater than 49% inhibition of wheal area, and 74% inhibition of flare area were maintained for 8 hours following the 30 mg and 60 mg dose.  No statistically significant increase in mean QTc interval compared to placebo was observed in 714 adult subjects with seasonal allergic rhinitis given fexofenadine hydrochloride capsules in doses of 60 mg to 240 mg twice daily for 2 weeks.  		87636	5333	236474	D006632
Fexofenadine hydrochloride	histamine	13	11	true	positive	Histamine skin wheal and flare studies in 7 to 12 year old subjects showed that following a single dose of 30 mg or 60 mg, antihistamine effect was observed at one hour and reached a maximum by 3 hours.  Greater than 49% inhibition of wheal area, and 74% inhibition of flare area were maintained for 8 hours following the 30 mg and 60 mg dose.  No statistically significant increase in mean QTc interval compared to placebo was observed in 714 adult subjects with seasonal allergic rhinitis given fexofenadine hydrochloride capsules in doses of 60 mg to 240 mg twice daily for 2 weeks.  		87636	5333	236474	D006632
terfenadine	Histamine	1	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  		42330	5333	42330	D006632
terfenadine	Histamine	1	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  		42330	5333	42330	D006632
terfenadine	Histamine	1	3	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  Fexofenadine hydrochloride inhibited antigen-induced bronchospasm in sensitized guinea pigs and histamine release from peritoneal mast cells in rats.  		42330	5333	42330	D006632
terfenadine	Histamine	1	3	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  Fexofenadine hydrochloride inhibited antigen-induced bronchospasm in sensitized guinea pigs and histamine release from peritoneal mast cells in rats.  		42330	5333	42330	D006632
terfenadine	histamine	1	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  		42330	5333	42330	D006632
terfenadine	histamine	1	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  		42330	5333	42330	D006632
terfenadine	histamine	1	3	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  Fexofenadine hydrochloride inhibited antigen-induced bronchospasm in sensitized guinea pigs and histamine release from peritoneal mast cells in rats.  		42330	5333	42330	D006632
terfenadine	histamine	1	3	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  Fexofenadine hydrochloride inhibited antigen-induced bronchospasm in sensitized guinea pigs and histamine release from peritoneal mast cells in rats.  		42330	5333	42330	D006632
